With a 'monopoly' on gly­co­pro­teomics, In­ter­Venn rais­es $34M to push can­cer di­ag­nos­tic in­to the clin­ic, woos Il­lu­mi­na BD ex­ec

For a few years now, ear­ly de­tec­tion of can­cer has been the sex­i­est top­ic in all of di­ag­nos­tics. With bil­lions of VC dol­lars poured in­to the pur­suit of tests to sniff out tu­mors ear­ly, the field is full of new ap­proach­es that promise to ac­cu­rate­ly pick up traces of can­cer, when pa­tients are more like­ly to be cured. But amid all the -omics — rang­ing from next-gen­er­a­tion ge­net­ic se­quenc­ing to high-through­put pro­tein screen­ing — one par­tic­u­lar type of mol­e­cule is al­ways ab­sent.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.